Home » Stocks » Immunomedics

Immunomedics, Inc. (IMMU)

Stock Price: $40.54 USD 0.54 (1.35%)
Updated Aug 12, 2020 2:20 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 9.37B
Revenue (ttm) 20.37M
Net Income (ttm) -353.41M
Shares Out 231.14M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $40.54
Previous Close $40.00
Change ($) 0.54
Change (%) 1.35%
Day's Open 40.08
Day's Range 39.73 - 40.80
Day's Volume 772,997
52-Week Range 8.80 - 44.91

More Stats

Market Cap 9.37B
Enterprise Value 8.40B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 231.14M
Float 204.66M
EPS (basic) -1.73
EPS (diluted) -1.70
FCF / Share -1.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 26.44M
Short Ratio 11.00
Short % of Float 12.82%
Beta 3.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 460.04
PB Ratio 16.82
Revenue 20.37M
Operating Income -313.00M
Net Income -353.41M
Free Cash Flow -260.44M
Net Cash 965.74M
Net Cash / Share 4.18
Gross Margin -1,249.82%
Operating Margin -1,536.66%
Profit Margin -1,735.10%
FCF Margin -1,278.59%
ROA -25.16%
ROE -100.04%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 9
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$52.24*
(28.86% upside)
Low
40.0
Current: $40.54
High
60.0
Target: 52.24
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.30-3.093.235.659.044.9632.7314.7160.93
Revenue Growth---4.39%-42.81%-37.48%82.22%-84.84%122.54%-75.86%-
Gross Profit0.30-2.612.075.397.514.5732.3114.2959.97
Operating Income-325-145-79.15-59.01-46.22-35.58-11.421.44-17.9133.93
Net Income-357-158-153-59.04-48.00-35.43-11.381.38-14.2437.00
Shares Outstanding19418910594.7793.3184.6378.0475.4875.3175.20
Earnings Per Share-1.84-0.84-1.47-0.62-0.51-0.42-0.150.02-0.190.49
Operating Cash Flow-222-131-62.25-48.46-39.00-30.69-5.904.91-12.19-7.07
Capital Expenditures-6.85-11.21-1.84-2.23-0.92-0.38-0.60-0.57-0.61-0.68
Free Cash Flow-229-142-64.09-50.69-39.92-31.07-6.504.34-12.79-7.75
Cash & Equivalents61349815550.6399.6241.8341.3332.8427.1030.49
Total Debt17.077.0698.0897.3596.62-----
Net Cash / Debt59649156.82-46.732.9941.8341.3332.8427.1030.49
Assets67252816356.9510647.4947.9338.6434.3246.12
Liabilities4042622221141108.638.134.476.685.40
Book Value268267-58.69-56.82-3.9139.3540.1834.4627.8240.72
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immunomedics, Inc.
Country United States
Employees 366

Stock Information

Ticker Symbol IMMU
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMMU

Description

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. It also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company has clinical collaboration with AstraZeneca, MedImmune, and Roche; collaboration agreement with The Bayer Group; clinical and preclinical collaborations with academic cancer institutions; and research collaboration with the Memorial Sloan Kettering Cancer Center. It also has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.